rx1 and pax6 are necessary for the establishment of the vertebrate eye field and for the maintenance of the retinal stem cells that give rise to multiple retinal cell types. They also are differentially expressed in cellular layers in the retina when cell fates are being specified, and their expression levels differentially affect the production of amacrine cell subtypes. To determine whether rx1 and pax6 expression after the eye field is established simply maintains stem cell-like qualities or affects cell type differentiation, we used hormone-inducible constructs to increase or decrease levels/activity of each protein at two different neural plate stages. Our results indicate that rx1 regulates the size of the retinal stem cell pool because it broadly affected all cell types, whereas pax6 regulates more restricted retinal progenitor cells because it selectively affected different cell types in a time-dependent manner. Analysis of rx1 and pax6 effects on proliferation, and expression of stem cell or differentiation markers demonstrates that rx1 maintains cells in a stem cell state by promoting proliferation and delaying expression of neural identity and differentiation markers. Although pax6 also promotes proliferation, it differentially regulates neural identity and differentiation genes. Thus, these two genes work in parallel to regulate different, but overlapping aspects of retinal cell fate determination.
Introduction
The development of the retina involves the interplay of many factors at several developmental time points. Embryonic precursors are biased toward a retinal fate by interactions and signaling factors that pattern the early embryo (reviewed in Zaghloul et al., 2005) . At neural plate stages signaling from the underlying mesoderm establishes the eye field, whose cells are specified to give rise to the retina by several genes, such as rx1, pax6 and six3 (reviewed in Wawersik and Maas, 2000; Marquardt and Gruss, 2002; Zuber et al., 2003; Zaghloul et al., 2005) . These genes continue to be expressed in retinal stem (RSC) and progenitor (RPC) cells in the optic vesicle, optic cup and ciliary marginal zone (CMZ) of the mature retina.
Numerous homeodomain and bHLH transcription factors are subsequently involved in specifying the different retinal cells types (reviewed in Hatakeyama and Kageyama, 2004; Zaghloul et al., 2005; Wang and Harris, 2005) . However, those genes that initiate the eye field also are differentially expressed in retinal layers as the retina matures (Hirsch and Harris, 1997; Harris and Perron, 1998; Perron et al., 1998; , suggesting that they also may play a role in cell type specification. It has been difficult to study their potential additional functions at later developmental times, however, because they are required for the initial establishment of the eye field (Hill et al., 1991; Grindley et al., 1995; Mathers et al., 1997; Hirsch and Harris, 1997; Gehring and Ikeo, 1999; Fitzpatrick and van Heyningen, 2005) .
Although several early lineage studies suggested that retinal cell type specification was a late event in retinogenesis, labeling of individual eye field cells demonstrated that the eye field contains at least two different types of RSC/RPC that give rise to either multipotent or restricted lineages reviewed in Zaghloul et al., 2005) . The eye field also is characterized by molecular heterogeneity; the three retinal stem cell genes (rx1, pax6, six3) are expressed in overlapping, but not identical, patterns in the eye field, suggesting that RSCs and subsequent RPCs express different combinations of these genes. For example, differential expression of homeodomain transcription factors in conjunction with bHLH transcription factors in retinal progenitors alters their contribution to mature retinal cell types (Wang and Harris, 2005) . Furthermore, since different neurotransmitter subtypes of amacrine cells are derived from different sets of embryonic precursors Moody, 1995, 1997) , and inner nuclear layer (INL) cells (which include amacrine cells) arise from restricted progenitors in the eye field , it is possible that differential expression of the RSC genes may initiate the process of amacrine cell specification shortly after they establish the eye field. To test this possibility, we made hormone-inducible constructs of rx1 and pax6 to alter the expression levels of these genes after the eye field is formed. We found that increased levels of Rx1 in the early eye field promotes neuropeptide Y (NPY) amacrine cells and represses GABA and dopamine (DA) amacrine cells, and in the late eye field significantly represses DA and NPY phenotypes (Zaghloul and Moody, 2007) . Increased levels of Pax6 in the early eye field represses NPY and DA amacrine cells but does not affect the GABA phenotype, and in the late eye field significantly represses only the DA phenotype. These results indicate that levels of Rx1 and Pax6 differentially modify the ability of cells in the eye field to produce the different neurotransmitter subtypes of amacrine cells.
To determine if the effects reported above are specific to amacrine subtypes, herein we extend these analyses to representative cells in all of the retinal layers for two reasons. First, since rx1 and pax6 are considered important for the maintenance of RSCs and the ability to give rise to multiple cells types in the retina (Marquardt et al., 2001; Casarosa et al., 2003) , their increased levels may in fact repress the differentiation of all cell types. Second, based on their later expression patterns in the layered retina, if they promote specification of certain cell types, one would expect: 1) rx1 to promote cell types located in the outer nuclear layer (ONL) and outer portion of the INL (OINL) and/or repress those in the inner portion of the INL (IINL) and ganglion cell layer (GCL); and 2) pax6 to promote cell types located in the IINL and GCL and/or repress those in the ONL and OINL. Our results suggest that rx1 regulates the size of the RSC pool because it broadly affected all retinal cell types, whereas pax6 regulates the formation of certain types of RPCs because it selectively affected different cell types in a time-dependent manner. Analysis of the effects of altering the levels/activity of Rx1 and Pax6 on proliferation, and expression of stem cell or differentiation markers demonstrates that rx1 maintains cells in a stem cell state by promoting proliferation and delaying expression of neural identity and differentiation markers. Although pax6 also promotes proliferation, it does not maintain stem cell markers but differentially regulates neural identity and differentiation genes. We propose that these two genes work in parallel to regulate different, but overlapping aspects of retinal cell fate determination during the eye field stages.
Materials and methods

Generation and collection of embryos
Fertilized Xenopus laevis embryos were obtained from adult frogs induced to mate after injection of human chorionic gonadotropin. After chemical removal of the jelly coat, embryos were selected as previously described (Moody, 2000) to target the major blastomere precursor of the retina (blastomere D1.1.1; Huang and Moody, 1993) .
Targeted microinjection of synthetic mRNAs
To increase protein levels at desired developmental times, hormoneinducible vectors of rx1 (Mathers et al., 1997) and pax6 (Hirsch and Harris, 1997) were constructed by fusing their coding regions to the ligand-binding domain of the human glucocorticoid receptor (GR) by PCR (described in Kolm and Sive, 1995; Zaghloul and Moody, 2007) . For loss-of-function experiments, hormone-inducible constructs containing the coding regions of previously characterized dominant-negative rx1 (rx1EnR; Andreazzoli et al., 1999) and dominant-negative pax6 (dnpax6; Chow et al., 1999) were similarly made (Zaghloul and Moody, 2007) . Capped, polyadenylated mRNAs were synthesized in vitro (Ambion, Inc.) and mixed at concentrations of known phenotypes (rx1, 50 pg; pax6, 50 pg; rx1EnR, 400 pg; dnpax6, 60 pg) with gfp (150 pg) or βgal (100 pg) mRNA as lineage tracers. Each experimental mRNA mixture was microinjected (1 nl) into blastomere D1.1.1 on one side of the embryo. Exogenous gene expression was targeted to this blastomere, which produces 50-60% of retinal cells (Huang and Moody, 1993) , to avoid a global effect on the eye field that might perturb later retinogenesis.
After mRNA injection, the cells synthesize the fusion proteins, but the GR domain forms a complex with endogenous heat shock proteins that prevents the transcription factor from entering the nucleus (Mattioni et al., 1994; Kolm and Sive, 1995) . To uncouple this complex and allow nuclear translocation, injected embryos were incubated in synthetic hormone (10 μM dexamethasone) according to published protocols (Kolm and Sive, 1995) . To ensure that the GR constructs function as expected, injected embryos were treated with hormone immediately after mRNA injection; for each construct these embryos phenocopied those injected with the non-GR versions (Hirsch and Harris, 1997; Mathers et al., 1997; Andreazzoli et al., 1999; Chow et al., 1999) , as reported in Zaghloul and Moody (2007) . For the experiments reported herein, embryos were continuously exposed to hormone starting at two different time points in eye field development (stage 12, early neural plate; stage 16, neural fold; Nieuwkoop and Faber, 1994) to discern whether there is a time window for the observed effects. Experiments in tissue culture and in whole embryos with similar GR-fusion constructs indicate that robust protein activation occurs rapidly (within 90 min) after hormone treatment, and is maintained for several days (Hollenberg et al., 1993; Mattioni et al., 1994; Kolm and Sive, 1995; De Graaf et al., 1998) . Therefore, we assume that the GR-fusion proteins are available to affect downstream targets throughout the culture period of our experiments. To demonstrate that the GR-constructs have no effects in the absence of hormone, we previously injected embryos with the GR-constructs and raised them in the absence of hormone; no morphological abnormalities were observed and dopamine amacrine cell numbers were unchanged from controls (Zaghloul and Moody, 2007) in accord with published accounts (Hollenberg et al., 1993; Mattioni et al., 1994; Kolm and Sive, 1995; De Graaf et al., 1998) . To demonstrate that hormone treatment alone does not affect differentiated retinal cell fates, we previously injected control embryos with only gfp mRNA and treated them with dexamethasone at eye field stages; cell counts of dopamine amacrine cells from these embryos were identical to those from gfp mRNA-injected embryos not exposed to hormone (Zaghloul and Moody, 2007) . Furthermore, dexamethasone treatment of control embryos did not alter the mean number of apoptotic cells in the optic vesicle (1.34 ± 0.22), as assessed by the TUNEL assay (see below) compared to untreated embryos (1.85 ± 0.27; p > 0.05). Dexamethasone treatment of control embryos also did not change the types of tissues populated by the D1.1.1 lineage (Fig. 3 ).
Immunostaining, cell counting, mitotic index determination and TUNEL assay
Embryos were raised in the continuous presence of hormone to stage 38 for analysis of horizontal cells or stage 44/45 for analysis of all other cell types, fixed in 4% paraformaldehyde solution (MEMFA; Sive et al., 2000) and scanned for GFP expression to analyze only embryos in which exogenous gene expression was successful. Embryos were cryoprotected overnight at 4°C in 30% sucrose/0.1M phosphate buffer solution, embedded in Tissue-Tek OCT medium (Miles, Inc.), and cut serially (14 μm) with a cryostat. Immunostaining was carried out as previously described (Huang and Moody, 1995) using rabbit anti-Calbindin D-28K (Chemicon) for cone photoreceptors (1:200) and rabbit anti-GABA (Immunostar, Inc.) for horizontal cells (1:500). AlexaFluorconjugated Texas Red goat anti-rabbit IgG secondary antibodies (Molecular Probes) were applied at a concentration of 1:200. Sections were analyzed using an epifluorescence microscope equipped with a dual pass GFP/Texas Red barrier filter set. The total number of immunolabeled cells was counted in every section through the retina, and the proportion of those that were also labeled with GFP (i.e., derived from the genetically altered lineage) was calculated. To identify ganglion cells, sections were incubated in 4, 6-diamidino-2-phenylindole (DAPI) (1:5000) to label cell nuclei, and all nuclei within the GCL were counted. Percent contributions of the D1.1.1 lineage to a particular cell type from each experimental condition were compared to those from gfp mRNAinjected control embryos that were similarly treated with dexamethasone (n = 10 embryos per data set) by the Student's unpaired t-test (α < 0.05); each treatment data set passed the equal variance test.
Proliferating cells were identified by immunostaining with an antibody that recognizes the phosphorylated state of histone H3 (PH3). This protein is expressed only in cells which are in the prophase of mitosis (Hendzel et al., 1997) . To determine the mitotic index of clones, the number of cells in the clone (marked by cytoplasmic β-Gal) expressing PH3 as well as the total number of cells (labeled by DAPI nuclear staining) in the clone were counted at optic vesicle stages (stage 20/21). The mean mitotic indices for dexamethasonetreated control (n = 12) and experimental (n = 10 per group) groups were compared by the Student's unpaired t-test, as above.
To determine whether alterations in gene expression caused apoptotic cell death, β-gal (control) and experimental mRNA-injected embryos were treated with dexamethasone at stage 12 and raised to stages 21/22 and 25/26. After fixation in MEMFA, the vitelline membranes were removed and the embryos were stained for the presence of β-Gal to identify the injected side of the embryo. The embryos were post-fixed and further processed for the TUNEL assay according to the manufacturer's protocol (In Situ Cell Death Detection Kit, AP; Roche). After the chromogenic reaction using BM Purple (Roche), embryos were fixed, bleached to remove skin pigment and cleared with BB/BS. The number of apoptotic cells within the retina was counted and compared by the Student's unpaired t-test, as above.
In situ hybridization
Embryos were fixed in MEMFA to visualize gene expression at optic vesicle (stages 20-22), optic cup when the first post-mitotic cells appear (stages 25-28), embryonic retina when the first born cells begin to differentiate (stages 32-34), and early larval retina when all cell types have begun to differentiate (stage 38). A histochemical reaction was done to visualize the location of the β-Gal labeled cells and in situ hybridization carried out according to standard protocols using digoxygenin-labeled antisense RNA probes (Sive et al., 2000) . In all experiments control embryos were treated with dexamethasone. rx1, pax6 and six3 probes were used as markers of retinal stem cells. notch1 and sox2 probes were used as markers of neural stem cells. ngn1, p27, neuroD and Xath5 were used as markers of early differentiation. Effects of altering gene levels starting at stage 12 versus stage 16 were compared by Chi-square analyses to detect potential temporal differences in gene effects. To visualize expression domains in the late retina (stage 38), whole mount preparations were sectioned with a vibratome. To determine whether increased levels of Rx1 or Pax6 caused D1.1.1 progeny to change from a retinal fate, embryos also were analyzed for expression of chordin (dorsal mesoderm), Nkx2.4 (ventral forebrain) and pax2 (optic stalk) and a lineage map of the D1.1.1 clone was constructed (Moody, 1987) .
Calculation of retinal volumes and optic cup size
To determine effects on the volume of the differentiated retina, both control and experimental mRNA injected embryos were treated with hormone at stage 12 and raised to stage 44/45. Embryos were fixed in MEMFA, cryoprotected overnight in 30% sucrose solution and sectioned at 14 μm with a cryostat. The area of each section through an entire retina was measured from a video image captured directly from the microscope using a Hamamatsu Argus-10 image processor. The volume of each retina was calculated by summing the section area and multiplying by section thickness. To determine whether the effects were manifested at the initiation of retinal development, the width of the optic cups, stained by in situ hybridization with rx1 probe, in stage 25 experimental and control mRNA-injected, hormone-treated embryos were measured with a stereomicroscope equipped with an eyepiece micrometer. Widths were expressed as the number of divisions (arbitrary units) of the eyepiece micrometer at 64X magnification. For both sets of measurements, mean values for dexamethasone-treated control (n = 12) and experimental (n = 10 per group) values were compared by the Student's unpaired t-test, as above.
Results
Changes in Rx1 levels/activity at eye field stages affect several retinal cell types
In the layered Xenopus retina, rx1 is expressed both in the RSC of the CMZ and in cells in the ONL and OINL. Previous work demonstrated that increasing rx1 levels after eye field formation reduces three amacrine cell subtypes (Zaghloul and Moody, 2007) , promotes photoreceptor cell fate (reviewed in Bailey et al., 2004) and represses ganglion cell fate (Sakagami et al., 2003) . This might occur because increasing Rx1 levels at this stage: (1) preferentially promotes ONL and OINL cell types and/ or represses IINL (e.g., amacrine) and GCL cell types; or (2) maintains a multipotent cell state that retards the differentiation of all cell types. To distinguish between these possibilities, markers for cells in the other retinal layers were analyzed. At stage 44/45, cone photoreceptors (ONL) are specifically labeled with calbindin antibodies and ganglion cell nuclei (GCL) can be identified by DAPI staining; at stage 38, GABA antibodies label horizontal cells (OINL) (Figs. 1A-C).
To avoid altering Rx1 levels during the specification of the initial RSCs that constitute the eye field, the Rx1-GR protein was activated by hormone at either early (stage 12) or late (stage 16) neural plate stages. If rx1 acts to promote ONL and/or OINL cell types at these stages, then cone and horizontal cell numbers should increase after increasing Rx1 levels and decrease after Rx1 loss-of-function. If rx1 acts to suppress IINL and GCL cell types at these stages, then amacrine and ganglion cell number should decrease after increasing Rx1 levels and increase after rx1 loss-of-function. Instead, increasing rx1 levels within the D1.1.1 lineage at either stage significantly reduced all monitored cell types (Figs. 1D-F); GABA amacrine cells, which account for about 95% of the amacrine cells at this developmental stage in Xenopus (Huang and Moody, 1998) , also were decreased (Zaghloul and Moody, 2007) . Because all cell types are reduced by increased Rx1 levels, this gene appears to promote an undifferentiated RSC state at these stages rather than specific cell type formation. This reduction is not likely to be due to increased cell death because the mean number of apoptotic cells per retina at either stage 21 (0.85 ± 0.25) or stage 26 (1.85 ± 0.46) was not different from dexamethasone treated controls (p > 0.05).
Decreasing rx1 target gene activation with the rx1EnR-GR construct beginning at stage 12 reduced the number of ganglion cells, whereas cone and horizontal cell numbers did not change significantly (Figs. 1G-I). Decreasing rx1 target gene activation beginning at stage 16 significantly increased cone and ganglion cell numbers but did not affect horizontal cells (Figs. 1G-I). GABA amacrine cell numbers also were increased at both stages of hormone treatment (Zaghloul and Moody, 2007) . These loss-of-function data indicate that: (1) early neural plate expression of rx1 is required for ganglion cells, but the other cell types can differentiate in its absence; and (2) late neural plate expression of rx1 is not required for any of the cells types; in fact rx1 probably inhibits the differentiation of cone, GABA amacrine and ganglion cells since their cell numbers increase in its absence. Since the mean number of apoptotic cells per retina at stage 21 (0.80 ± 0.16) or stage 26 (1.65 ± 0.30) did not differ from dexamethasone-treated controls (p > 0.05), these observations are not the result of selective cell death.
Changes in Pax6 levels/activity at eye field stages selectively affect retinal cell types
In the layered retina, pax6 is expressed both in the RSC of the CMZ and in cells in the IINL and GCL. Previous work demonstrated that increasing levels of pax6 after eye field formation reduces only DA and NPY amacrine cells, two rare subtypes, but has no detectable effect on the major amacrine subtype that expresses GABA (Zaghloul and Moody, 2007) , consistent with a conditional loss-of function mouse mutant showing that pax6 is required for all cell types except amacrine cells (Marquardt et al., 2001) . To test whether increasing Pax6 levels at this stage preferentially promotes IINL and GCL cell types and/or represses ONL and OINL cell types, Pax6-GR was activated by hormone at two different neural plate stages. Increasing Pax6 levels at stage 12 significantly repressed horizontal cells, increased ganglion cells and did not change cone cell numbers, whereas increasing Pax6 levels at stage 16 only repressed cone cells (Figs. 2A-C). GABA amacrine cell numbers were unaffected at either stage (Zaghloul and Moody, 2007) . The observed reduction in cell numbers is not likely to be due to increased cell death because the mean number of apoptotic cells per retina at either stage 21 (0.60 ± 0.15) or stage 26 (1.75 ± 0.48) was not different from dexamethasone treated controls (p > 0.05).
Decreasing Pax6 activity by activating the dnPax6-GR protein at stage 12 significantly increased horizontal cell numbers but had no detectable effect on cone or ganglion cells (Figs. 2D-F). In contrast, decreasing Pax6 activity at stage 16 significantly increased cone and ganglion cell numbers, whereas horizontal cell numbers were not affected (Figs. 2D-F). GABA amacrine cell numbers were increased after pax6 loss-offunction at both stages (Zaghloul and Moody, 2007) . These observations are not likely to be due to increased cell death because the mean number of apoptotic cells per retina at either stage 21 (0.80 ± 0.19) or stage 26 (1.35 ± 0.17) was not different from dexamethasone treated controls (p > 0.05). Together these data indicate that after the eye field forms, increased pax6 levels at stage 12 preferentially promote ganglion cells and repress horizontal cells, and at stage 16 preferentially repress cone cells.
To ensure that these changes in retinal cell types are not the result of retinal lineages being diverted to other cell fates, we monitored the D1.1.1 lineage in βGal, rx1-GR and pax6-GR mRNA injected embryos. In all cases the D1.1.1 cells populated their normal tissues (cf. Moody, 1987) , including diencephalon, retina, epidermis and branchial arch mesoderm, both in the presence and absence of hormone ( Fig. 3 ). Increasing Rx1 (n = 20) or Pax6 (n = 20) also did not alter the expression of chordin, a dorsal mesoderm gene, nor was the distribution of D1.1.1 progeny within this tissue different from controls (data not shown). Further, the expression patterns of a ventral forebrain gene (Nkx2.4) and an optic stalk gene (pax2) were not altered by mRNA injection or hormone treatment and there was no evidence that β-Gal expressing cells were diverted out of the retina into the alternate ventral diencephalic domains of these genes (Fig. 3) . These results indicate that the reduction in the D1.1.1 contribution to retinal cell types following increased levels of Rx1 or Pax6 at eye field stages is not due to the cells changing fate to populate other tissues or CNS domains.
Rx1 promotes a proliferative, undifferentiated RSC state
Previous studies showed that rx1 overexpression resulted in ectopic eye tissue, whereas loss of rx1 by gene knockout in mice or by expression at blastomere stages of a dominantnegative construct in Xenopus resulted in the formation of a small eye (Mathers et al., 1997; Andreazzoli et al., 1999) . These results and our observation that increased Rx1 levels decreases the numbers of differentiated cells in all layers ( Fig. 1) are consistent with the suggestion that rx1 maintains a stem-like, multipotent state (Casarosa et al., 2003) . If true, then increased Rx1 levels should increase cell proliferation, maintain stem cell marker genes longer through development and/or expand their expression domains, and delay or repress differentiation marker genes. If instead rx1 affects retinal cell type specification, then increased Rx1 levels should have differential effects on neural identity and differentiation genes that promote certain cell types (reviewed in Hatakeyama and Kageyama, 2004) .
Increasing Rx1 levels at stage 12 resulted in a significant increase in the proportion of mitotic cells within the clone at optic vesicle stages (stage 20/21) compared to controls (Figs. 4A, D, E); conversely, decreasing Rx1 target gene activation resulted in a significant decrease (Figs. 4A, F). These data correlate with significant increases in the size of the early optic cup (stage 25) and mature retina (stage 44) after increasing Rx1 and significant decreases in rx1 loss-of-function embryos (Figs. 4B, C). After both Rx1 increase and rx1 loss-of-function, the differences between control and injected retinas were less dramatic in the mature retina, suggesting that the effect is attenuated over time. These results demonstrate that rx1 expression in the eye field is necessary and sufficient to expand the proliferative pool of cells from early optic vesicle stages throughout embryonic retinogenesis.
If rx1 affects retinal cell fates simply by expanding and/or maintaining the RSC pool as predicted from the proliferation data, then increased Rx1 levels should expand the expression of retinal stem cell genes and repress the expression of differentiation genes. To test this, several marker genes were analyzed at different stages of retinal development. pax6 and six3 were used as markers of RSCs. Both are expressed in the early eye field and continue to be expressed throughout the optic vesicle, optic cup, and all zones of the CMZ. In addition, as layers develop pax6 and six3 are expressed in the GCL and INL Figs. 5A, D-G) . notch1 and sox2 were used as markers of neural stem cells. notch1 is expressed in the developing nervous system, including the optic vesicle, optic cup, zone 2 and 3 of the CMZ, GCL and INL, and inhibits the differentiation of cells (Coffman et al., 1993; Figs. 5A, H, I) . sox2, a member of the Group B1 Sox genes, functions to maintain undifferentiated neural precursors (Sasai, 2001; Bylund et al., 2003) and is expressed in the optic vesicle, optic cup, CMZ, GCL and INL (Figs. 5A, J, K). Both notch1 and sox2 are thought to maintain the neural identity of nervous system stem cells (Hitoshi et al., 2002; Graham et al., 2003) . ngn1, p27, neuroD and Xath5 were used as markers of differentiation. ngn1 is a bHLH factor that promotes neuronal differentiation upstream of other neurogenesis genes (Ma et al., 1996) and is expressed in the optic cup and all layers of the central retina; it is absent from the CMZ at stage 38 (Figs. 5A, L, M). p27 is a cyclin-dependent kinase inhibitor that inhibits cell cycle genes, and promotes cell cycle exit and subsequent differentiation by interacting with and stabilizing bHLH proteins (Su et al., 1995; Ohnuma et al., 1999; Vernon et al., 2003) . It is expressed in the optic cup, zones 2 and 3 of the CMZ, GCL and INL (Figs. 5A, N, O) . neuroD, a bHLH gene, is expressed later than ngn1 in the optic cup, zone 3 of the CMZ, GCL and INL, and promotes the formation of differentiated neurons (Lee et al., 1995; Figs. 5A, P, Q) . Xath5 is a proneural bHLH factor expressed exclusively in the optic cup, zone 3 of the CMZ and GCL of the developing retina and interacts with other factors in the retina to promote the differentiation of retinal neurons (Kanekar et al., 1997; Figs. 5A, R, S) . Our observations, made at stage 38, indicate that rx1, pax6 and six3 are expressed by RSCs (zones 1, 2, 3) and RPCs (zones 2, 3) in the CMZ and in different subsets of differentiating cells in the forming layers. notch1 is expressed in RPCs (zones 2, 3) and some differentiating cells. sox2 is expressed by RSCs, RPCs and some differentiating cells. ngn1 is expressed by differentiating cells whereas p27, neuroD and Xath5 are expressed in subsets of RPCs (zone 3) and different subsets of differentiating cells. The expression patterns observed here are consistent with those previously published for stage 44 Ohnuma et al., 1999) . The expression patterns for all of these genes in dexamethasone treated control embryos were indistinguishable from untreated controls (not shown). Fig. 3 . Activation of Rx1-GR or Pax6-GR protein at stage 12 does not cause cells to contribute to alternate cell fates. Cells descended from the mRNA-injected D1.1.1 blastomere (red) contribute to head tissues in a pattern identical to normal fate maps (cf. Moody, 1987) , including diencephalon (d), lateral epidermis (e), retina (r; outlined), and branchial arch mesoderm (ba). These patterns are consistent regardless of which mRNA was injected (βGal, rx1, pax6), and whether hormone (dex) was added to the culture medium. The expression domains of Nkx2.4 in the ventral diencephalon and pax2 in the optic stalk did not change after any of the treatments. Bar = 100 μm.
Expression of stem cell markers throughout the zones of the CMZ provides evidence that the cells located in those regions are the earliest RSCs whereas expression of differentiation markers in zones 2 and 3 of the CMZ suggest that the cells located there are more mature RPCs that are in transition between a stem cell state and the differentiating cells located in the layers of the central retina.
Markers were analyzed at early optic vesicle (stages 20-23), optic cup (stages 25-28) when the first post-mitotic cells appear, embryonic retina (stage 32; early differentiation) and early larval retina (stage 38) when all cell types have begun to differentiate and all cell layers begin to form. Rx1-GR protein was activated at early (stage 12) and late (stage 16) neural plate stages to identify any potential temporal differences in its effects. Two aspects of expression of each marker were independently determined. First, embryos were scored for whether the marker gene was expressed in the β-Gal labeled cells that were expressing the construct; this would indicate a cell autonomous effect on gene expression. Second, embryos were scored for the size of the domain of marker gene expression; this would indicate whether a particular pool of cells was altered.
Increasing Rx1 levels at either stage 12 or 16 resulted in an initial (stage 20) repression of both RSC markers (pax6, six3; Table 1 ). The expression domains were smaller (Figs. 6A, C) and both genes were repressed in β-Gal labeled cells (e.g., Fig.  6A inset). The same effects were observed in embryos through early differentiation stages, albeit with a gradual decrease in frequency (Table 1) . Thus, rx1 appears to both repress pax6 and six3 autonomously (in β-Gal cells) and to reduce the size of the pax6+/six3+ RSC pools, as indicated by smaller expression domains in optic vesicles/cups that are significantly larger in size ( Fig. 4) . At stage 38, in which a more mature, though not fully layered, retina has developed, pax6 or six3 remained repressed in β-Gal labeled cells in some embryos (e.g., Fig. 6B ) but recovered in others (e.g., Fig. 6D ); their expression domains were similar to controls (Table 1) demonstrating that the effects are transient. A statistical comparison of the frequency of repression after increasing Rx1 levels at stage 16 only detected a more prolonged effect on pax6 at stage 32 and a more transient effect on six3 (Table 1) , indicating that rx1 has a slightly more persistent effect on pax6 expression. notch1 and sox2 expression were similarly reduced initially (stages 20-22) in β-Gal labeled cells (Fig. 6E inset) and their domains were smaller (Table 1 ; Figs. 6E, G). Thus, rx1 autonomously repressed the expression of these genes, reducing the pool of cells that had acquired a neural identity. These effects decreased in frequency at later stages (Table 1) . When Rx1 levels were increased at stage 12, the effects on notch1 and sox2 expression were restored to normal in the majority of embryos by stage 38 (Figs. 6F, H). A similar trend was seen when Rx1 levels were increased at stage 16, but for both genes the effects were more transient ( Table 1 ), suggesting that by stage 16 many cells had already acquired neural identity. Thus, increased Rx1 levels appear to initially delay the acquisition of neural identity/stem cell gene expression, and the rapid recovery suggests that this effect may only occur during the developmental window between neural plate and optic cup.
Markers of neural differentiation were analyzed starting at stage 25, when they are first detectable in the developing retina. Increasing Rx1 levels at either stage strongly repressed all four markers at stages 25-32, including both expression domain size (Figs. 6I, K, M, O) and in β-Gal labeled cells (e.g., Fig. 6I inset; Table 1 ). The frequency of repression was reduced by stage 38 for all four genes (Table 1) but was still detectable in β-Gal labeled cells (Figs. 6J, L, N, P). Thus, increasing Rx1 levels at early or late neural plate stages repressed both the onset of differentiation and the size of the pool of differentiating cells. This appears to be independent of neural identity expression because after stage 16 activation of Rx1-GR, notch1 and sox2 expression are nearly recovered whereas differentiation genes are still strongly reduced. Although some previous studies suggest that rx1 is an upstream regulator of pax6 (Zuber et al., 2003) , decreasing rx1 target gene activation by Rx1EnR-GR beginning at either stage did not alter the expression of either RSC or neural stem/identity markers in β-Gal labeled cells (Table 1 ; e.g., Fig. 7E inset) . The expression domains of these genes all were smaller (Figs. 7A, C, E, G), as expected because the optic vesicle and retina were smaller (Fig. 4) . In embryos in which rx1 loss-of-function was activated at stage 12, the reduction in expression domain size at stage 38 was less severe for all genes except sox2, consistent with the less severe reduction in retinal volume compared to optic cup (Fig. 4) . Further, β-Gal labeled cells expressed the RSC and neural stem/identity markers (Figs. 7B, D, F, H) . These results demonstrate that rx1 activity after the initial formation of the eye field is not required for the maintenance of other RSC markers or for the acquisition of neural identity.
Activating Rx1EnR-GR at either stage reduced the expression domains of all four differentiation markers (Table 1; Figs. 7I, K, M, N) . Although the decrease in expression domain size for all markers was probably the result of a smaller optic vesicle and retina (Fig. 4) , repression also was observed surrounding β-Gal cells (e.g., insets in Figs. 7M, O) . This repression in β-Gal cells was detectable for all four differentiation markers at stage 38 (Figs. 7J, L, N, P), but the frequency was reduced (Table 1) . For ngn1 and p27, this cellular repression was dramatic at stages 25 and 32; expression recovered in the majority of embryos by stage 38 when Rx1EnR-GR was activated at stage 12 but continued to be significantly repressed when activated at stage 16 (Table 1) . For neuroD, cellular repression was greatly reduced by stage 38 after rx1 loss-of-function at either stage. For Xath5, the frequency of repression was only moderate at all stages after Rx1EnR-GR activation at stage 12, whereas it was dramatic at all stages after Rx1EnR-GR activation at stage 16. Since the β-Gal cells express RSC and neural identity genes, these results support the hypothesis that rx1 expression is required for RSCs/RPCs to initiate differentiation. The more dramatic repression of differentiation markers after stage 16 rx1 loss-of-function indicates that rx1 becomes more integral to differentiation at late neural plate stages.
Pax6 also promotes proliferation, but differentially affects neural identity and differentiation markers
Previous studies showed that increasing Pax6 levels results in ectopic eye tissue, whereas repressing Pax6 activity in knockout mice or by expression at blastomere stages of a dominant-negative construct in Xenopus results in the formation of a small eye (Hill et al., 1991; Chow et al., 1999; Kenyon et al., 2001) . These results suggest that pax6 establishes and/or maintains RSCs. Similar to rx1, increasing Pax6 levels significantly increased the mitotic index of the injected clone (Fig. 4A) . Concordantly, the optic cup and mature retina were significantly larger than controls (Figs. 4B, C) . pax6 loss-offunction significantly reduced the mitotic index and reduced the size of the optic vesicle and mature retina (Figs. 4A-C). The changes in retinal size were less severe in the mature retina suggesting that the effect is attenuated over time. These findings indicate that pax6 also is necessary and sufficient to expand the proliferative pool of cells from optic vesicle stages throughout retinogenesis; thus, it has a function redundant with rx1.
To determine whether increasing Pax6 levels at eye field stages affects stem cell and/or differentiating populations, overexpression studies were performed as above. The domain of rx1 expression was larger transiently after Pax6-GR activation at stage 12 (Fig. 8A) , likely due to the increased size of the developing retina (Fig. 4) , whereas the six3 domain did not change (Fig. 8C ), suggesting that rx1-and six3-expressing RSCs are differentially expanded by pax6 in the early eye field. When Pax6-GR was activated at stage 16, both rx1 and six3 domains were transiently decreased ( Table 2 ), suggesting that pax6-expressing RSCs were promoted at the expense of rx1and six3-expressing RSCs. At no stage did β-Gal labeled cells show repression of rx1 or six3 (Table 2 ; Figs. 8B, D); expression was neither repressed when β-Gal labeled cells were located in regions of endogenous staining nor ectopically expressed when β-Gal cells were located outside those regions. Expression domains of neural identity genes were differentially affected after increasing Pax6 levels (Table 2 ; Figs. 8E-H). notch1 expression did not change except for the initial and transient decrease in domain size after the activation of Pax6-GR at stage 16. At no stage did β-Gal labeled cells show repression of notch1 (Table 2 ; Fig. 8F ). However, sox2 expression was repressed after Pax6-GR activation at stage 12; this effect was strongest at stage 20 and greatly reduced by stage 38 (Table 2 ; Fig. 8G ). Interestingly, the opposite effect was observed after Pax6-GR activation at stage 16; patches of ectopic sox2 expression surrounding β-Gal labeled cells outside the retina were observed at all stages (Table 2 ; Fig. 8H ). This latter effect is consistent with the report that pax6 expression can promote the formation of neural ectoderm (Grindley et al., 1995) . These data demonstrate a time-dependent effect on sox2 by increased levels of Pax6. Early Pax6-GR activation appears to delay the transition to a neural RPC, whereas later activation promotes neural identity. These effects are independent of notch1 expression.
Similar to rx1, activation of Pax6-GR at either stage 12 or stage 16 repressed all four markers of differentiation (Table 2) . Increasing Pax6 levels at stage 12 strongly repressed ngn1 and p27 domains (Figs. 8I, K) and this effect persisted in β-Gal labeled cells through stage 38 (Figs. 8J, L) . In contrast, neuroD and Xath5 were repressed in only about half of the embryos (e.g., Figs. 8M, O) , and this effect declined considerably by stage 38 (Table 2) . However, when repression was noted, it occurred in β-Gal labeled cells ( Figs. 8N, P) . Increasing Pax6 levels at stage 16 also repressed both ngn1 and p27, but the effect recovered by stage 38 (Table 2) . Both neuroD and Xath5 expression were more highly repressed by increasing Pax6 levels at stage 16 and this persisted through stage 38. These results demonstrate differential temporal effects of increasing Pax6 on the genes known to regulate the initiation of differentiation. The earliest expressed differentiation genes (ngn1, p27) were repressed more strongly by Pax6-GR activation at stage 12, whereas the later expressed differentiation genes (neuroD, Xath5) were repressed more strongly by Pax6-GR activation at stage 16. Thus, pax6 expression at different developmental times is likely to differentially affect RPCs and later cell phenotypes.
Although some previous studies suggest that pax6 is an upstream regulator of rx1 and six3 (Chow et al., 1999) , pax6 loss-of-function by activating the dnPax6 protein at either stage 12 or stage 16 neither repressed nor caused ectopic expression of either RSC marker (Table 2) . Although their expression domains were smaller (Fig. 9A, C) , this probably was due to the smaller size of the retina (Fig. 4) . At no stage did β-Gal labeled cells show repression of rx1 or six3 (Figs. 9B, D) . The expression domain of notch1 was normal after stage 12 treatment ( Fig. 9E ) but reduced after stage 16 treatment (Table 2) , whereas sox2 was reduced at both ( Fig. 9G ; Table  2 ). But at no stage did β-Gal labeled cells show repression of. notch1 or sox2 (Table 2, Fig. 9E inset, F, H) . These results demonstrate that after initial eye field formation neither RSC nor neural identity genes require pax6.
Markers of differentiation were repressed differentially after pax6 loss-of-function at eye field stages and these effects varied with the onset of the loss (Table 2) . When Pax6 activity was reduced at stage 12, ngn1 expression was reduced in all embryos (Fig. 9I) ; this effect recovered somewhat by stage 38 but β-Gal labeled cells often repressed ngn1 expression ( Fig.  9J ). When Pax6 activity was reduced at stage 16 there was a less dramatic repression of ngn1 that recovered more rapidly ( Table   Table 1 Changes in marker gene expression after altering Rx1 levels/activity Differentiating neurons
Differentiating neurons (cell cycle exit) (20) (19) The percentage of embryos showing an effect on marker gene expression in β-Gal labeled cells (Expression), and the percentage of embryos showing an effect on the size the marker gene expression domain (Domain) is shown for each stage analyzed. ↓ indicates decreased expression or smaller domain; NC indicates no change in expression or domain size;indicates that analysis was not done at that stage because the gene is not yet expressed in the developing retina. Numbers in parentheses denote sample size. ⁎ Indicates significant difference compared to stage 12 (p < 0.01). 2). Similar effects were observed for p27 expression (Table 2; Figs. 9K-L). In contrast, reduced Pax6 activity at either stage 12 or stage 16 had no observable effect on neuroD expression in β-Gal labeled cells, even though the expression domain was transiently smaller (Table 2 ; Figs. 9M-N) . The domain of Xath5 and its expression in β-Gal labeled cells were reduced in less than half the embryos when Pax6 activity was reduced at stage 12 and the effect recovered by stage 38 (Table 2 , Figs. 9O-P). However, when Pax6 activity was reduced at stage 16 Xath5 expression was profoundly and persistently reduced ( Table 2 ). These results demonstrate that the expression of ngn1, p27 and Xath5 require pax6 during different windows of eye field stages (ngn1, p27 earlier; Xath5 later), whereas expression of neuroD is independent of pax6.
Discussion
The retina provides a useful model in which to study the specification of neural cell types. Its limited number of cells that differentiate in a fixed temporal sequence and spatial pattern has facilitated studies of cell fate specification. Much work has focused on the genetic mechanisms that direct cell differentiation at the latest stages of retinal development after eye cup formation (reviewed in Hatakeyama and Kageyama, 2004) , but little is known about how earlier events affect this process. rx1 and pax6 are both expressed at the initial formation of the eye field and are crucial for the production of the retinal stem cells (RSCs); lossof-function of either results in severe eye defects and increased expression of either causes ectopic retinal tissue. However, both genes continue to be expressed as cells begin to differentiate and populate the different retinal layers, suggesting that they have additional roles in cell type specification. Because these two genes are highly expressed during neural plate stages, when biased progenitors are forming , we sought to determine whether these two key regulators of retinogenesis have differential roles in this initial period of cell type specification. This was accomplished by both increased expression and loss-of-function using hormone-inducible gene constructs in order to bypass the critical time period in which rx1 and pax6 are both required to establish the eye field.
Analyzing changes in the number of specific cell types representing each retinal layer, produced by the genetically Fig. 7 . rx1 is not required after stage 12 for other retinal stem or neural identity marker genes but is necessary for the onset of differentiation markers. (A) pax6 expression domain in the optic vesicle (arrow) is smaller (cf. Fig. 5D ). (B) At stage 38, the pax6 expression domain is normal, and no repression surrounds β-Gallabeled nuclei (arrowheads). (C) six3 expression domain in the optic vesicle (arrow) is smaller (cf. Fig. 5F ). (D) At stage 38, there is no repression of six3 surrounding the β-Gal-labeled nuclei (arrowheads). (E) notch1 expression domain in the optic vesicle is smaller (arrow). However, cells with β-Gal labeled nuclei (inset, arrowheads) express notch1. (F) At stage 38, notch1 expression is similar to controls and no repression surrounds β-Gal labeled nuclei (arrowheads). (G) sox2 expression domain in optic vesicle (arrow) is smaller (cf. Fig. 5J ). (H) At stage 38, there is no repression of sox2 expression surrounding the β-Gal labeled nuclei (arrowheads). (I) ngn1 expression in the optic cup (arrow) is greatly reduced (cf. Fig. 5L ). (J) At stage 38, ngn1 expression continues to be repressed surrounding β-Gal labeled nuclei (arrowheads). (K) p27 expression in the optic cup (arrow) is greatly reduced (cf. Fig. 5N ). (L) At stage 38, p27 expression is repressed surrounding β-Gal labeled nuclei (arrowheads) in some embryos. (M) neuroD expression in the optic cup (arrow) is greatly reduced (cf. Fig. 5P ). Inset: cells with β-Gal-labeled nuclei (arrowheads) do not express neuroD. (N) At stage 38, neuroD expression continues to be repressed in β-Gal-labeled cells (arrowheads). (O) Xath5 expression in the optic cup (arrow) is greatly reduced (cf. Fig. 5R ). Inset: cells with β-Gal-labeled nuclei (arrowheads) do not express Xath5. (P) At stage 38, Xath5 continues to be repressed in β-Gal-labeled cells (arrowheads). Data for stage 16 activation are similar albeit at higher frequencies for differentiation genes (see Table 1 ). Dashed lines indicate the outline of the retinas in the sectioned material. For whole mounts, bars = 100 μm; for sections bars = 20 μm. modified D1.1.1 lineage suggest that rx1 maintains an RSC pool because it broadly affected all cell types, whereas pax6 regulates retinal progenitor cell (RPC) specification because it selectively affected different cell types in a time-dependent manner (Fig.  10) . Analyzing the effects of increasing Rx1 and Pax6 levels or decreasing their activity on proliferation and the expression of RSC, neural identity and differentiation marker genes demonstrate that rx1 promotes proliferation, represses other RSC genes as well as neural identity and differentiation marker genes. Although pax6 also promotes proliferation, it does not affect the other RSC genes or notch1, but represses sox2 and differentiation genes. Thus, these two genes have similar but not identical roles in regulating the early steps of retinal cell fate.
rx1 establishes and maintains retinal stem cells rx1 is necessary for the formation of the eye, probably as a result of its role in establishing the definitive RSCs. In Xenopus, strong rx1 expression is initially detected at stage 12 when the eye field is established, but weak expression can be detected Fig. 8 . Increasing Pax6 levels at stage 12 does not alter stem cell marker genes but represses sox2 and differentiation marker genes. (A) rx1 expression in the optic vesicle (arrowhead) is larger (cf. Fig. 5B ). (B) At stage 38, rx1 expression is similar to controls and no repression surrounds β-Gal-labeled nuclei (arrowheads). (C) six3 expression in the optic vesicle (arrowhead) is not different from the control side. (D) At stage 38, no repression of six3 expression surrounds β-Gal-labeled nuclei (arrowhead). (E) notch1 expression in the optic vesicle on the injected side (arrowhead) is similar to the control side. (F) At stage 38, no repression of notch1 expression surrounds β-Gal-labeled nuclei (arrowheads). (G) When Pax6-GR protein is activated at stage 12, the sox2 expression domain in the optic vesicle is smaller (arrow). (H) When Pax6-GR protein is activated at stage 16, sox2 expression in the optic vesicle domain is smaller (arrow), but in the neural plate (np) it is broader and is ectopically expressed (arrow, inset). (I) ngn1 expression in the optic cup (arrowhead) is fainter and reduced in size (cf. Fig. 5L ). (J) At stage 38, repression of ngn1 in β-Gal labeled cells persists (arrowheads). (K) p27 expression in the optic cup (arrowhead) is fainter and reduced in size (cf. Fig. 5N ). (L) At stage 38, repression of p27 expression in β-Gal labeled cells (arrowheads) persists. (M) neuroD expression in the optic cup is fainter and reduced in size (cf. Fig. 5P ). (N) At stage 38, neuroD expression remains repressed (arrowheads) in only a small number of embryos (Table 2 ). (O) Xath5 expression in the optic cup (arrow) is fainter and reduced in size (cf. Fig. 5R ). (P) At stage 38, Xath5 expression remains repressed in β-Gal labeled cells (arrowhead) in a small number of embryos (Table 2) . Data for stage 16 activation (except for sox2, see H above) are similar albeit at significantly lower frequencies at stage 38 for ngn1 and p27 and at higher frequencies for neuroD and Xath5 (Table 2) . Dashed lines indicate the outline of the retinas in the sectioned material. For whole mounts, bars = 100 μm; for sections bars = 20 μm. during gastrulation (Mathers et al., 1997; Mathers and Jamrich, 2000; Zuber et al., 2003) . This suggests that rx1 is present prior to eye field formation, and perhaps directs the genetic pathway involved in that process. When rx1 is inactivated in mouse prior to gastrulation, there are severe eye defects or no eyes develop, indicating that rx1 plays a key role in establishing the multipotent RSCs that comprise the eye field. The maintenance of rx1 expression throughout eye field, optic vesicle and optic cup stages, when different RPCs are being produced, and in the CMZ in the differentiating retina suggests that rx1 plays an additional role in maintaining an RSC pool during retinogenesis. Our observations that increased Rx1 levels during neural plate stages increased proliferation and the size of the retina, and decreased Rx1 activation of target genes had the opposite effect, support this interpretation.
However, the observation that rx1 also is expressed in differentiated ONL and OINL cells suggests that it plays an additional later role in the specification of these cell types. To distinguish which of these latter two roles are in play during eye field stages, it is necessary to be able to manipulate gene expression after the establishment of the RSCs. Utilizing hormone-inducible rx1 constructs demonstrated that increased Rx1 levels at either early or late neural plate stages repressed or delayed the differentiation of representative cell types in each of the retinal layers (data herein and Zaghloul and Moody, 2007) . Conversely, rx1 loss-of-function at neural plate stages increased the numbers or promoted the differentiation of 3 of the 4 cell types monitored. These results are consistent with a report that overexpression of rx1 in optic cup cells by DNA transfection results in the production of all cell types, indicating a role for rx1 in maintaining multipotency (Casarosa et al., 2003) . Together these studies indicate that rx1 plays a key role in maintaining RSCs in a proliferative, multipotent stem state at least through optic cup stages. To determine whether rx1 has a later role in determining ONL and OINL fates new methods for controlling the temporal expression of constructs are needed, as hormones do not penetrate the Xenopus embryo very well once the neural tube closes.
If rx1 is the initial regulatory gene in the RSC pathway, and its increased expression maintains cells in the RSC state, then increasing Rx1 levels at neural plate stages would be expected to expand the expression of two other RSC genes, pax6 and six3. However, increasing Rx1 levels represses these two genes, and rx1 loss-of-function indicates that their expression is independent of rx1 in RSCs. These results are consistent with previous studies that show that: (1) loss of rx1 expression in knockout mice does not affect the initial expression of other genes expressed in the region of the anterior neural plate that gives rise to RSCs, including otx2, six3 and pax6 (Zhang et al., 2000) ; and (2) rx1 over-expression at blastomere stages results in a slight repression of otx2, six3 and pax6 (Andreazzoli et al., 1999) . Based on previous studies that the expression domains of rx1, pax6 and six3 overlap but are not identical in the eye field, and that the eye field contains a heterogeneous pool of progenitor cells (reviewed in Zaghloul et al., 2005) , we propose that a high level of Rx1 promotes the maintenance of a primitive RSC, which is proliferative and multipotent, and feeds back on other RSC marker genes to maintain their expression at lower levels (Fig. 10) . Consistent with this model, increased Rx1 levels at neural plate stages also represses downstream effectors of differentiation. The expression of two neural identity markers, notch1 and sox2, was delayed; these genes maintain Fig. 5L ). (J) At stage 38, ngn1 continues to be repressed surrounding β-Gal labeled nuclei (arrowhead). (K) p27 expression in the optic cup (arrow) is fainter (cf. Fig. 5N ). (L) At stage 38, p27 expression continues to be repressed surrounding clusters of β-Gal labeled nuclei (arrowheads). (M) neuroD expression domain in the optic cup (arrow) is reduced in size but not expression intensity (cf. Fig. 5P ). (N) At stage 38, neuroD expression is not repressed in β-Gal labeled cells (arrowheads). (O) Xath5 expression domain in optic cup (arrow) is fainter in less than half of the embryos (cf. Fig. 5R ). (P) At stage 38, Xath5 expression is not repressed in β-Gal labeled cells (arrowheads). Data for stage 16 activation are similar, but at significantly different frequencies for differentiation genes (see Table 2 ). Dashed lines indicate the outline of the retinas in the sectioned material. For whole mounts, bars = 100 μm; for sections bars = 20 μm.
a neural identity in RPCs by allowing the subsequent expression of neuronal differentiation genes (Van Raay et al., 2005) . Increased Rx1 levels also repressed the expression of four different neural differentiation genes, and caused a general decrease in the production of all monitored cell types, presumably by decreasing or delaying the onset of differentiation. Together these data support the proposal that elevated levels of Rx1 promote the maintenance of a primitive multipotent, undifferentiated RSC. There are some differential effects of altered Rx1 levels/ activity on particular cell types that are not simply explained by prolonged maintenance of primitive RSCs. If rx1-positive RSCs produce RPCs whose fates are simply defined by the temporal order of their generation, one would expect that early manipulation of Rx1 levels would affect all cell types, whereas later manipulation would primarily affect later born cell types (cones, amacrines) and spare early born cell types (ganglion, horizontal) . The results from increasing Rx1 levels do not follow this pattern; one late cell type (amacrine) was profoundly repressed early (stage 12) and significantly less so later (stage 16). Thus, Rx1 levels may also affect the specification of certain types of RPCs during neural plate stages. For example, the RPCs identified in the stage 14/15 neural plate that are biased towards amacrine and IINL fates may be repressed by increasing Rx1 levels at stage 12 and refractive to this manipulation by stage 16. Because six3 is thought to be important in promoting amacrine cell fate (Marquardt et al., 2001; Inoue et al., 2002) , it is possible that increased Rx1 levels repress amacrine fate by repressing six3-positive RSCs/RPCs at these stages (Fig. 10) .
pax6 plays multiple roles in retinal development pax6 also plays a key role in the establishment of the eye field. In Xenopus, its initial expression can be strongly detected at stage 12.5 but weak expression can be detected during gastrulation (Hirsch and Harris, 1997; Zuber et al., 2003) . Inactivation of pax6 in mice prior to gastrulation represses eye development (Hill et al., 1991; Grindley et al., 1995) , although it may act downstream of rx1 because pax6 loss-of-function mutants are less severe . In addition, pax6 likely maintains RSC and RPC throughout retinogenesis because it is expressed in these cells in the neural plate, optic vesicle, optic cup and CMZ. Furthermore, increased Pax6 levels promote RSC/RPC proliferation and decreased Pax6 activity reduces proliferation ( Fig. 4 ; Philips et al., 2005) .
In addition to its role in establishing the eye field, we propose that shortly after the formation of the eye field, pax6 promotes the formation of a restricted RSC subtype (Fig. 10 ). Like rx1, increased or decreased Pax6 levels/activity altered proliferation and the size of the retina, indicating that the pax6-positive cells are RSCs. But pax6 did not change the expression of the other RSC genes (rx1, six3), suggesting that the pax6-positive cells are more restricted than the multipotent rx1-positive primitive RSCs. Also, altered Pax6 levels/activity had differential effects on the downstream genes, indicating that the pax6-positive cells are different from the rx1-positive primitive RSCs. Unlike rx1, Pax6 does not affect the expression of notch1; this observation is consistent with the report that notch1 may act upstream of pax6 (Onuma et al., 2002) . When Pax6 levels are increased at stage 12, sox2 expression is reduced, whereas increasing Pax6 at stage 16 expands sox2 expression. These findings indicate that during the window between early and late neural plate stages pax6 plays different roles in regulating sox2-mediated aspects of neural identity. Because sox2 is necessary for the maintenance of neural identity and subsequent differentiation of RPCs (Van Raay et al., 2005) , initial repression of sox2 by Pax6 may maintain restricted RSCs and RPCs and delay cells from becoming biased RPCs (Fig. 10) . This interpretation is consistent with the observation that loss of pax6 in mice leads to premature retinal differentiation (Philips et al., 2005) . Conversely, the later induction of sox2 expression by pax6 may facilitate the transition from RPC to biased RPC and subsequent onset of differentiation.
Previous work also indicates that pax6 has a role in specifying certain cell types. In the differentiating retina, pax6 continues to be expressed in the cells of the IINL and GCL. Furthermore, eliminating pax6 expression at optic cup stages depletes the subsequent formation of all cell types except amacrine cells (Marquardt et al., 2001) . Our analyses of cell types in the differentiated retina also indicate that altered Pax6 levels/activity at neural plate stages affect cell fate specification. Both horizontal cells and cone photoreceptors, which reside in the two cell layers (OINL, ONL, respectively) in which pax6 is Fig. 10 . Proposed differential functions of Rx1 and Pax6 during early steps in retinal development. High levels of Rx1 maintain the retinal stem cell (RSC) in a primitive, proliferative, multipotential state. As levels of Rx1 are reduced, the RSC becomes more restricted and when the levels of other RSC genes (Pax6, Six3) differentially rise, RSCs transition to become retinal progenitor cells (RPCs). The onset of expression of neural identity genes (e.g., Sox2, Notch1) creates RPCs that are biased to a neural fate; differential expression levels of these genes may create different subtypes of biased RPCs. Our data indicate that after the formation of the eye field, continued high levels of Rx1 at stage 12 maintain primitive RSCs and prevent or delay the transition to restricted RSCs. Continued high levels of Rx1 at stage 16 also promotes primitive RSCs and reduces the expression of Pax6-and Six3-expressing RPCs. In contrast, continued high levels of Pax6 at stage 12 reduce the primitive RSCs and promote restricted RSCs and Pax6-expressing RPCs. These latter cells repress the expression of Sox2 in biased RPCs. Continued high levels of Pax6 at stage 16 reverse the repression of Sox2 expression. not expressed in the mature retina, were repressed by increased Pax6 levels and expanded by reduced Pax6 activity. Interestingly, the effects on horizontal cells were only apparent when Pax6 levels were increased at stage 12 and the effects on cone cells were only apparent when Pax6 levels were increased at stage 16. This difference in timing correlates with the generation of horizontal cells earlier than cone cells.
The effects on ganglion cells also are consistent with the normal expression pattern of pax6 in the GCL. Increasing Pax6 levels at stage 12 promotes ganglion cells, whereas there is no significant effect at stage 16; this temporal difference may be due to the fact that ganglion cells are generated first and, therefore, later manipulations may be less effective. However, the reduction of Pax6 activity at stage 12 did not affect ganglion cell numbers, although these cells are lost when pax6 is eliminated in the optic cup (Marquardt et al., 2001) . This suggests that pax6 loss-of-function at neural plate stages is not sufficient to eliminate ganglion cells, perhaps due to compensation by other eye field factors. For example, recent work has defined a regulatory network of genes that specifies ganglion cell fate (reviewed in Mu and Klein, 2004) . Not only are there many genes in this pathway that may compensate for each other, but the proper levels of expression and timing of expression are likely to be important in producing enough ganglion cells as well as limiting their numbers.
Consistent with studies showing that knockdown of pax6 during optic cup stages results in the nearly exclusive production of amacrine cells (Marquardt et al., 2001) , reduction of Pax6 activity at both early and late neural plate stages resulted in an increase in amacrine cells (Zaghloul and Moody, 2007) . Since increased Pax6 levels at either stage did not repress GABA-positive amacrine cells, which represent approximately 95% of all amacrine cells (Huang and Moody, 1998) , it is unlikely that pax6 specifically represses amacrine cells. It is more likely that a reduced level of Pax6 activity is permissive for other factors that promote amacrine cell fate. For example, Marquardt et al. (2001) also showed that factors involved in amacrine fate are unaffected by repression of pax6. However, it is interesting that a small subset of amacrine cells, those that express DA, are repressed by increasing Pax6 levels during neural plate stages (Zaghloul and Moody, 2007) . Whether there also are differential effects on the more than 20 different amacrine subtypes will require further investigation.
The differential effects of altering Pax6 levels/activity in the neural plate on neural identity and differentiation genes also indicate a role for this gene in the early steps of cell type specification. When Pax6 levels were increased at stage 12, ganglion cell numbers increased, consistent with a previous report that the repression of sox2 expression in the optic vesicle results in an increase in ganglion cells (Van Raay et al., 2005) . By stage 16, however, increasing Pax6 levels increased sox2 expression and the ganglion cell numbers were no longer affected, suggesting that the role of pax6 in ganglion cell fate via sox2 regulation occurs during a defined temporal window in the neural plate. We illustrate this as occurring at the transition between RPC and biased RPC (Fig. 10 ), but this needs to be experimentally tested.
When Pax6 activity at neural plate stages is decreased, markers of differentiation are lost with the exception of neuroD. This is consistent with findings in knockout mice that pax6 expression is necessary for the expression of many differentiation genes but not for neuroD (Marquardt et al., 2001) . Thus, the onset of neuroD expression appears to be independent of pax6 activity. However, the levels of ngn1 and p27 expression were altered by increasing and decreasing Pax6 levels/activity during neural plate stages. They were most strongly affected by altered Pax6 levels/activity at stage 12, whereas Xath5 was most strongly affected by altered Pax6 levels/activity at stage 16. Because these different bHLH factors are implicated in the production of different retinal cell phenotypes, pax6 may regulate, in a time-dependent manner, the production of different subtypes of RPCs.
Altering Pax6 levels/activity affected the size of two neuronal populations, consistent with published effects of altered neuroD expression. Increased Pax6 levels had no effect on the number of amacrine cells produced, but pax6 loss-offunction promoted the formation of amacrine cells (Zaghloul and Moody, 2007) . In mice, pax6 knockout in the optic cup resulted in continued neuroD expression and the overproduction of amacrine cells (Marquardt et al., 2001) , and neuroD promotes amacrine cell fate when over-expressed in the presence of Math3 (Inoue et al., 2002; Morrow et al., 1999) . Thus, neuroD appears to be required for amacrine cell production, and pax6 appears to limit the size of the amacrine cell population by repressing neuroD. The regulation of neuroD by pax6 is also important for photoreceptor specification. Misexpression of neuroD in the developing retina results in the increased production of photoreceptors (Yan and Wang, 1998) . In our studies, increasing Pax6 levels at neural plate stages repressed neuroD and decreased cone photoreceptors. Decreasing Pax6 activity did not alter neuroD expression and photoreceptors formed in greater numbers. Thus, Pax6 levels/ activity at neural plate stages play a role in maintaining the correct size of amacrine and photoreceptor populations in the retina by regulating neuroD activity.
The effect of pax6 on specification of cell types through neuroD activity may be related, in part, to effects on ngn1 and Xath5. ngn1 is thought to be upstream of neuroD function in the photoreceptor pathway . Increasing Pax6 levels at either neural plate stage resulted in a repression of ngn1 expression, and thus might be involved in regulating the photoreceptor population. However, pax6 loss-of-function resulted in a reduction of ngn1 expression, indicating that neither pax6 nor ngn1 expression is necessary for neuroD promotion of cone photoreceptor differentiation at these stages. It will be important to investigate whether pax6 has similar effects on rod photoreceptors, which are the most abundant subtype of photoreceptor cell. These cells are particularly difficult to quantify in our paradigm due to their very large numbers in the Xenopus tadpole retina. Xath5 is also thought to be upstream of neuroD in photoreceptor specification (Ma et al., 2004) . In our experiments, increasing Pax6 levels resulted in a decrease in Xath5 expression, a decrease in neuroD expression and a decrease in photoreceptor numbers, consistent with this model. However, as described for ngn1, pax6 loss-of-function resulted in a decrease in Xath5, whereas neuroD expression and photoreceptor numbers increased. These results indicate that Xath5 is not necessary for cone photoreceptor production. In order to elucidate the different pathways that may be downstream of pax6 for photoreceptor production, other factors need to be tested.
pax6 effects on p27 expression also may affect cell type specification. p27 drives cell cycle exit and premature expression causes cells to differentiate into early born cell types such as ganglion cells and photoreceptors (Ohnuma et al., 1999) . In our experiments, p27 expression was decreased when Pax6 levels were increased at either stage and with pax6 lossof-function at stage 12. However, p27 expression was only moderately affected transiently by pax6 loss-of-function at stage 16. This correlates with the observed increase of ganglion cells and cone photoreceptors, the earliest born cell types, after stage 16 activation of dnPax6-GR. The persistence of p27 expression under this experimental condition may promote the differentiation of these two cell types.
In summary, manipulating Rx1 and Pax6 levels/activity in retinal stem and progenitors cells after the formation of the eye field demonstrates that these two genes have differential effects on the further differentiation of these cells. In general, increased Rx1 levels appear to repress the production of cell types from each retinal layer, whereas rx1 a loss-of-function expands nearly all these cell types. Rx1 appears to cause these changes by expanding a pool of primitive RSCs, thereby prolonging proliferation, decreasing the expression of other retinal stem and neural identity genes and repressing the expression of genes involved in neuronal differentiation. In contrast, increased Pax6 levels promote ganglion cells and represses ONL and OINL cells in a time-dependent manner, and decreasing Pax6 activity promotes different cell types at different stages. pax6 appears to define subsets of RSCs and RPCs that then form specific cell types in the mature retina. Thus, while Rx1 and Pax6 are both required for establishing the eye field, and are expressed in similar domains in the various stem/progenitor pools (neural plate, optic vesicle, optic cup, CMZ), their subsequent roles in the specification of RSCs and RPCs are cooperative but distinct.
